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a  b  s  t  r  a  c  t
hile  improvements  in  oral  rehydration  use  and  access  to healthcare  have contributed  to impressive  gains  in  child  survival,  diarrheal  diseases  remain
he  second  most  important  cause  of  child  mortality  in  India.  Pathogen  speciﬁc  disease  rates,  while  key  to deciding  on  the utility  of  speciﬁc  public  health
nterventions  such  as vaccines,  are  extremely  difﬁcult  to  obtain  in developing  country  settings  with  less  than  optimal  health  access,  diagnostic  services
nd  information  systems.
This  study  combined  disease  burden  within  ﬁve  cohorts  of infants  followed  up  for diarrheal  morbidity  with  data  from  the  nationally  representative
ndian  Rotavirus  Surveillance  Network  and  applies  rates  of  rotavirus  related events  to UNICEF  birth  and  mortality  estimates  for India.  These  estimates,
hile limited  by  the  lack of  data  from  nationally  representative  population  based  studies,  use  methods  consistent  with  those  employed  by the  World
ealth  Organization  Child  Health  Epidemiology  Reference  Group.
We estimate  that  11.37  million  episodes  of  rotavirus  gastroenteritis  occur  each  year  in India,  requiring  3.27 million  outpatient  visits  and  872,000
npatient  admissions  when health  access  is  unconstrained,  resulting  in  a need  for Rs.  10.37  billion  each  year  in  direct  costs.  An estimated  78,000  rotavirus-
ssociated deaths  occur  annually  of  which  59,000  occur  in  the ﬁrst 2  years  of life. Introduction  of  a rotavirus  vaccine  of  similar  efﬁcacy  to the Rotavac  in
he  national  immunization  program  would  result  in  686,277  fewer  outpatient  visits,  291,756  fewer  hospitalizations  and  26,985  fewer  deaths  each  year
n  India,  assuming  no indirect  effects  for  the vaccine.
©  2014 Published  by  Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
With concerted effort toward the Millennium Development
oals (MDG) there are now 14,000 fewer child deaths each day
cross the world as compared to 1990 [1,2]. Improvements in oral
ehydration solution (ORS) use and access to healthcare have con-
ributed to impressive gains in diarrheal mortality [3]. Decline
n pneumonia and diarrheal mortality have been instrumental in
lobal decline of under ﬁve mortality from 88 to 56 per 1000 live
irths by contributing over 40% of this decline [4,5]. Notwithstand-
ng the gains achieved in the past decade, over 700,000 children
ie each year of preventable diarrheal diseases in the develop-
ng world [2]. Developing countries such as India, where much of
he gains in mortality reduction of the past decade have accrued,
ack direct estimates of the extent, distribution and determinants
f this decline resulting in uncertainty regarding disease speciﬁc
stimates required for prioritizing public health strategies.
∗ Corresponding author at: Division of Gastrointestinal Sciences, Christian Medical
ollege, Vellore, TN 632004, India. Tel.: +91 416 228 2052.
E-mail address: gkang@cmcvellore.ac.in (G. Kang).
ttp://dx.doi.org/10.1016/j.vaccine.2014.03.004
264-410X/© 2014 Published by Elsevier Ltd. This is an open access article under the CC BAcute gastroenteritis remains a leading cause of post-neonatal
under-ﬁve mortality in India contributing about 13% of under-ﬁve
mortality [5,6]. Rotavirus is the most important cause for severe
gastroenteritis in this age group [2,7,8]. Studies in the last decade
estimate the annual mortality due to rotavirus in India to be
between 90,000 and 153,000 [4,9,10]. Debates on the public health
utility of rotavirus speciﬁc interventions are, in part, fueled by the
heterogeneity of mortality estimates and lack of data on the extent
of morbidity associated with the disease. Morbidity, an important
component of overall disease burden in developing countries,
is under-recognized especially in high mortality settings where
morbidity data is not readily available. Even where morbidity
data is available, they underestimate true healthcare need, as
socio-economic conditions, out of pocket spending and limited
health infrastructure are overwhelming determinants of health
access [11]. In situations with the highest burden of disease, health
information and laboratory systems are inadequately equipped to
detect and record etiology speciﬁc information.A newer, more affordable rotavirus vaccine developed through
an innovative social partnership may  soon be available. Availabil-
ity of affordable, efﬁcacious vaccines holds promise but challenges
policy makers to assess critically the burden of disease and the
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
A cine 3
a
m
c
e
f
t
n
t
o
2
2
N
c
w
t
s
d
e
i
h
t
a
d
a
h
d
A
a
a
i
i
o
w
i
(
a
d
r
r
a
w
f
2
r
o
b
t
t
t
b
[
m
c
e6 J. John et al. / Vac
nticipated impact in the local conditions. We  review the mortality,
orbidity and economic burden of rotavirus diarrhea in India in the
ontext of improving child survival and health access, and present
stimates of morbidity associated with rotavirus diarrhea from the
ollow up of ﬁve observational cohorts that were offered access
o healthcare without fees. This, we believe, represents morbidity
ot confounded by ﬁnancial and access to care-related issues and
herefore a more accurate measurement of the underlying burden
f disease.
. Methods
.1. Data sources
We  combined data from the Indian Rotavirus Strain Surveillance
etwork (IRSSN), the Million Death Study (MDS) [13] and statistics
ompiled by the World Health Organization (WHO) and UNICEF
ith data from ﬁve community-based cohorts to arrive at conserva-
ive estimates of the burden of rotavirus diarrhea across the disease
pectrum and the economic costs related to the disease.
The IRSSN is a geographically representative, hospital based
iarrheal surveillance system that used standardized protocols for
nrolment and diagnostic evaluation at eight sites across India dur-
ng 2005–2009 [12]. This surveillance system sampled diarrheal
ospitalization in the sentinel hospitals and provides the propor-
ion of hospitalized diarrhea that was related to rotavirus.
The Million Death Study (MDS), being conducted between 1998
nd 2014 by the Registrar General of India and collaborators to
etermine causes of death in India derives its data from a nation-
lly representative sample of 14 million people in 2.4 million
ouseholds within the Sample Registration System, a large, routine
emographic survey performed by the Registrar General of India.
ll deaths in the surveyed families have a cause of death assigned
ccording to the International Classiﬁcation of Diseases Revision 10
nd are characterized by age, gender and region [13].
Incidence of diarrhea, diarrheal outpatient visits and hospital-
zation was obtained from ﬁve community-based cohorts that were
ntensively followed up for enteric diseases till at least two  years
f age. Three of these cohorts were in Vellore while the fourth
as located in an urban slum in Delhi. Four of these cohorts also
nvolved rotavirus testing of diarrheal samples, while a ﬁfth cohort
also based in Vellore) had fortnightly follow-up and healthcare
ccess data but not rotavirus testing of diarrheal samples. The
etails of the ﬁve cohorts are presented in Table 1. The overall
ates of gastroenteritis, outpatient visits and hospitalizations due to
otavirus in the ﬁrst two years of life were obtained as a weighted
verage from the cohorts. The 95% conﬁdence intervals (95% CI)
ere calculated using the Byar’s approximation of the exact interval
or the Poisson distribution [17].
.2. Rotavirus related diarrheal mortality
The <5 diarrheal mortality rate (deﬁned as the number of diar-
heal deaths in children under ﬁve per 1000 live births) was
btained by the product of <5 mortality rate of 61 per 1000 live
irths for India [18] and the proportion of all <5 deaths attributed
o diarrhea in the Million Death Study (MDS) [10]
The rotavirus mortality rate was then estimated by applying to
he <5 diarrheal mortality rate the proportion rotavirus positive in
he IRSSN using methods and assumptions similar to those adopted
y the WHO  Child Health Epidemiology Reference Group (CHERG)
19,20]. The number of annual rotavirus deaths in India was  deter-
ined by applying the rotavirus mortality rate to the 2011 birth
ohort from UNICEF statistics. These numbers are compared with
stimates published previously [9,10].2S (2014) A5–A9
2.3. Rotavirus related diarrheal morbidity
The data from the ﬁve birth cohorts (Table 1) combined provide
rotavirus hospitalization rates for children under-two years of age.
Applying this rate to the entire under-ﬁve population would over-
estimate the burden, as the risk of rotavirus infection is greatest
in the ﬁrst two years. The proportion of diarrheal hospitalization
in the IRSSN that was  over three years of age was used as a correc-
tion factor to obtain a more conservative 3–5 year and a cumulative
<5 year rotavirus hospitalization rate. The number of hospitaliza-
tions attributable to rotavirus was  obtained by the product of the
rotavirus hospitalization rate and the number of children in the
2011 Indian birth cohort.
The ratio of outpatient rotavirus gastroenteritis visits to
rotavirus gastroenteritis admission in a phase III clinical trial pop-
ulation was 3.75. Applying this ratio to the number of hospitalized
rotavirus gastroenteritis episodes we arrive at the number of
rotavirus gastroenteritis outpatient visits. This ratio of ambulatory
to hospitalized rotavirus was  consistent with unpublished data
from CHAD Hospital; a 120 bedded community hospital in Vel-
lore that provides discounted care to a population of about 100,000
within its rural demographic surveillance system.
2.4. Potential impact of rotavirus vaccines
The vaccine efﬁcacy (VE) of three doses of Rotavac®, an oral
human-bovine natural reassortant vaccine obtained from a large
multicenter phase III trial in India was extrapolated to the risk
of rotavirus mortality, hospitalization and outpatient visits to
determine the number of deaths, hospitalizations and outpa-
tient visits potentially averted. Vaccine efﬁcacy against severe
rotavirus gastroenteritis, rotavirus hospitalization and all rotavirus
gastroenteritis were used to calculate impact against rotavirus
mortality, rotavirus hospitalization and rotavirus outpatient visits
respectively. Risk (deﬁned as the probability of event between 4
months and 5 years) is estimated by the expression cumulative
risk = (1 − exp(−
∑
rate*t)), where ‘rate’ refers to event rate and ‘t’
the time interval. For estimating the absolute risk of rotavirus
related events in the 4 month to 5 year period, we ﬁrst estimated
the event rate for the ﬁrst two  years of life as a weighted average
from the cohort and applied this to the four months to two  year
period to obtain risk estimates for the corresponding period. We
then obtained the 3–5-year incidence rate by applying to the 0–2
year incidence rate the relative proportion of cases that were 3–5
year old in the IRSSN study. Cumulating the incidence risk in the 4
months to 2 years with that in the 3–5 years provided the 4 months
to 5 years risk of rotavirus related events. The number needed to
vaccinate (NNV), under assumptions of no indirect effect, is pro-
vided by the inverse of the product of vaccine efﬁcacy and absolute
risk in the unvaccinated. We  assumed national immunization cov-
erage to be 74% and no herd protection while projecting the events
averted.
2.5. Healthcare costs due to rotavirus infection
The data for estimation of healthcare costs of rotavirus disease
was obtained from two  published studies [21,22], conducted in
2006 and 2009 respectively, that used the WHO  generic protocol
[23] to estimate the economic burden of diarrhea including direct
medical and non-medical (e.g., travel costs to and from the hospital)
costs through review of patient charts, healthcare facility records,
pharmacy records, and patient family interviews.
Healthcare costs, both hospitalizations and outpatient visits,
were divided into three levels – primary, secondary, and tertiary.
Secondary and tertiary level outpatient visits were further divided
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Table 1
Sources of diarrheal morbidity data in India and rotavirus speciﬁc disease rates.
Name of the
study
Location/time Sample
size
Follow-up
frequency
Rotavirus GE Rate per 1000 children
Hospitalizations Out-patient
visits
Episodes Reference
Cryptosporidium
transmission study
Vellore2008–2011 176 Weekly 12.8 47.8 121.2 [14,15]
Cryptosporidium
immune response
study
Vellore2009–2013 497 Biweekly 15.3 57.4 – Unpublished
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1MAL-ED cohort study Vellore2010–2014 251 Biweekly 
Lactobody study Vellore2011–2012 163 Weekly 
Delhi cohort Delhi 2009–2010 200 Weekly 
nto two categories – those that occur in ambulatory clinics and
hose that occur in emergency rooms. It was assumed that 15% of
ll outpatient visits for secondary and tertiary level care occurred
ia emergency visits and 85% occurred via ambulatory clinics. Also,
he proportion of rotavirus-related visits to primary, secondary and
ertiary levels of care were considered to be 33%, 41% and 26%
espectively, based on a multi-country estimate of healthcare uti-
ization patterns [24]. The healthcare costs were calculated by using
eights by the proportion of population that sought each level of
are and then multiplied by the total number of events. The total
ost of rotavirus-related hospitalizations and outpatient visits in
ndian children was calculated by multiplying the total number of
early healthcare encounters attributable to rotavirus for children
5 years of age by the costs of each encounter, weighted for the
roportion of population that sought each level of care.
All costs are reported in 2013 Indian rupees, adjusted for inﬂa-
ion. The Consumer Price Index (CPI) for India published by the
orld Bank was used for inﬂation-adjustment [25]. Total costs are
lso reported in U.S. dollars (1 USD = 60 INR).
Rotavac® was assumed to cost INR 50 per dose. It was also
ssumed that it would be administered within the current National
mmunization Schedule and the incremental administrative cost
er dose would not be more than INR 5 per dose. The total cost of
accinating 1 child with 3 doses of Rotavac® is estimated at INR
65.
. Results
.1. Rotavirus related mortality
The 2011 UNICEF under-ﬁve mortality rate for India is 61 per
000 live births. The MDS  estimates the proportionate mortality
ue to diarrhea in <5 year children to be 13.2%. Thus the under-
 diarrheal mortality rate in India is 8.04 per 1000 live births or
n annual mortality of 160.80 per 100,000 children. In the IRSSN,
405 (39%) of 3580 children hospitalized with diarrhea during this
eriod tested positive for rotavirus. Using WHO  CHERG approach
20] of applying rotavirus proportion in hospitalized diarrhea to
ortality data, the <5 rotavirus diarrhea mortality rate is 2.89/1000
ive births or an annual rate of 58 per 100,000 children. Applying
hese rates of mortality to the 2011 birth cohort of India, estimated
t 27,098,000 children, we estimate 78,583 deaths occur each year
ue to rotavirus with 59,336 of these deaths occurring in the ﬁrst
wo years of life.
.2. Rotavirus related morbidityBased on the 2241 child years of follow up in ﬁve birth cohorts,
ith 108 diarrheal hospitalizations including 32 rotavirus diarrheal
ospitalizations, the rotavirus hospitalization rate was  1427 per
00,000 children <2 years. The IRSSN data identiﬁed 88.2% of all10.7 40.1 217.5 Unpublished
13 48.8 292.5 Unpublished
16.1 60.2 160.6 [16]
<5 rotavirus diarrheal hospitalization occurs in children <2 years of
age [12] providing a corrected estimate of 643 hospitalizations per
100,000 children <5 years age or 872,000 hospitalizations annually
in India (Table 2).
Unpublished data from a large phase III clinical trial, where 1500
children in Vellore were followed up for the ﬁrst two  years life
and healthcare provided for without cost to participants, provide
a ratio of 3.75 rotavirus outpatient visits for every rotavirus hos-
pitalization. The number of rotavirus diarrheal episodes requiring
outpatient visit is thus estimated annually in India at 3,270,000.
The < 5 year rotavirus gastroenteritis rate in the four cohorts
where rotavirus testing was performed was 8394 episodes per
100,000 children. Extrapolating this rate to India’s < 5 population
11.37 million episodes of rotavirus diarrhea occur each year.
3.3. Impact of rotavirus vaccines
The vaccine efﬁcacy (VE) of Rotavac® against severe hospital-
ized rotavirus gastroenteritis was  53.6% and that against rotavirus
gastroenteritis of any severity was 34%. The 4 month to 5 year risk
of rotavirus related death, hospitalization and outpatient visit were
251, 2714, and 9891 per 100,000 children. Introduction of Rotavac®
in the National Immunization Program at current immunization
coverage would result in 26,985 fewer deaths, 291,756 fewer hos-
pitalizations and 686,277 fewer outpatient visits each year in India
assuming no indirect effects for the vaccine (Table 3).
The NNV to prevent one rotavirus related death was 743 chil-
dren, while vaccinating 69 children would prevent a rotavirus
hospitalization. Similarly, for every 29 children vaccinated one
rotavirus outpatient visit can be averted.
3.4. Healthcare costs
The median total direct cost (medical and non-medical) associ-
ated with rotavirus hospitalization was calculated at Rs. 8417 at a
tertiary care hospital, Rs. 6969 at a secondary level hospital and Rs.
1897 at a primary care hospital. For an outpatient visit the median
cost was Rs. 225. Weighting these costs by the estimated health-
care seeking patterns at each level, we estimate that hospitalization
due to rotavirus diarrhea cost the country INR 4.9 billion (3.3 to 6.9
billion) annually. Additionally the country spends about INR 5.38
billion (3.6–7.6 billion) on outpatient visits. The total cost of the
rotavirus immunization program for the 2011 India birth cohort
of 27,098,000 children was  calculated at Rs. 4.47 billion or USD
74.5 million, which is less than rotavirus associated hospitalization
costs.4. Discussion
Despite gains in child survival and increased availability of
effective interventions such as ORS, zinc and access to healthcare,
A8 J. John et al. / Vaccine 32S (2014) A5–A9
Table 2
Rotavirus disease burden estimates for India.
Burden Rotavirus mortality Rotavirus hospitalization Rotavirus outpatient visits Rotavirus gastroenteritis episodes
Rate (per 100,000 children under-5) 58 643.8 2414.3 8394
(95%  CI) (56.1–59.9) (440.3–908.9) (1651.4–3408.3) (7193–9738)
Number of annual events in India 78,583 872,315 3,271,187 11,373,098
(95%  CI) (76,019–81,206) (596,662–1,231,452) (2,237,486–4,617, 948) (9,745,967–13,194,028)
Table 3
Estimated impact of rotavirus vaccine introduction in India based on current disease burden and immunization coverage.
Annual Impact Rotavirus
mortality
Rotavirus
hospitalization
Rotavirus
outpatient
visits
Events averted with 74% coverage given current vaccine efﬁcacy 26,985 291,756 686,277
(LCI–UCI) (26,105–27,884) (220,225–410,097) (475,230–953,501)
Events  averted with 100% coverage given current vaccine efﬁcacy 36,466 394,265 927,401
(35,27
743 
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Number needed to vaccinate to prevent one event
CI–UCI, lower conﬁdence interval–upper conﬁdence interval.
otavirus diarrhea continues to result in substantial mortality and
orbidity for children in India and is a signiﬁcant economic burden
o the healthcare system and society. Each year in India, rotavirus
auses an estimated 78,500 deaths, 872,000 hospitalizations, and
ver 3.2 million outpatient visits in children <5 years of age. In other
ords, by 5 years of age, 1 in every 334 – 356 Indian children will die
rom rotavirus diarrhea, 1 in every 22 – 45 children will be hospital-
zed, and 1 in every 6 – 12 children will have visited an outpatient
linic for rotavirus diarrhea (Fig. 1). Despite the lower vaccine efﬁ-
acy of oral rotavirus vaccines in developing countries, because of
he large disease burden these vaccines are predicted to alleviate
ubstantial rotavirus mortality and morbidity [26]. Introduction of
otavac® at current national coverage, will avert 27,000 deaths,
91,000 hospitalizations and 686,000 outpatient visits annually.
The national estimates of rotavirus deaths are slightly lower
han rates previously estimated and are likely due to overall decline
n diarrheal mortality. Rotavirus continues to contribute 39% of
ll diarrhea hospitalizations reiterating its position as the most
Fig. 1. Estimated annual number and risk of death, hospitalization, outpatient visit8–37,681) (270,574–554,185) (642,202–1,288,515)
69 29
important cause of diarrheal mortality. This reduction in mor-
tality may  reﬂect a greater impact of interventions to improve
sanitation and hygiene on the burden of bacterial diarrhea, which
is often transmitted through contaminated food and water, as
opposed to rotavirus, which has multiple modes of transmission.
The decline in child mortality in the past two decades may  also
be a function of better access to ﬂuid replacement therapy and in-
patient healthcare [3]. Our estimates of rotavirus hospitalizations
are higher than previous estimates [9,19]. This may, in part, be a
result of lower threshold for hospitalization in intensely followed
up cohorts, but is also more likely to represent the true need for
hospitalization where there is no constraint to accessing health-
care and contributes signiﬁcantly to better survival. We  therefore
argue that our estimates of hospitalizations and outpatient care
reﬂect more accurately the demand on health resources, as access
constraints are removed through processes and structures estab-
lished in research studies. Our estimate of rotavirus outpatient
visits are lower than those estimated by Parashar and colleagues
s and diarrheal episodes due to rotavirus in children <5 years of age in India.
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8,9] because a conservative ratio of rotavirus outpatient visits to
ospitalization obtained from a phase III rotavirus vaccine trial
ohort of 1500 children observed for two years was used in which
wo-thirds of children had received a rotavirus vaccine. The ratio of
utpatient rotavirus gastroenteritis visits to rotavirus gastroenteri-
is admission in the phase III clinical trial population was  3.75, and
ay  have been lower because of the prompt administration of rehy-
ration solutions at home decreasing mild or moderate disease,
hich points again to higher need for healthcare due to rotavirus
isease than has previously been estimated. These are ﬁndings that
ust be considered as policy makers shift from impact estimation
ased on mortality alone to disease reduction.
This study has several limitations. First, four of the ﬁve cohorts
hat contributed to the estimation of rotavirus related morbidity
ere from a single site in Vellore. It is likely that morbidity rates
nd health-seeking characteristics of this population differs from
igher mortality regions of India and limits the validity of extrap-
lations from these geographically limited cohorts. Nonetheless,
iven that health characteristics and health care access in Tamil
adu are better than most other parts of India, it is likely that the
stimates based on Tami Nadu are very conservative. Second, the
5 mortality rate is the number of <5 deaths per 1000 live births in
 year and does not provide a direct estimate of probability of death
etween 0 and 5 years required for calculating deaths averted and
NV. Third, there is limited information on the rate of rotavirus
orbidity in the 3–5 year age group. This analysis assumes a con-
tant rate of events in the 4 months to 2 years age group and applies
n adjusted estimate to the 3–5 year age group where no or limited
irect estimates are available. Similarly we applied the ratio of
utpatient to inpatient rotavirus gastroenteritis among the clinical
rial participants to estimate the number of ambulatory rotavirus
astroenteritis visits. Despite there being no active referral to hos-
ital for diarrheal episodes, free and better healthcare access in
he clinical trial environment could have inﬂated the number of
utpatient visits. This must be considered against the underestima-
ion of the impact on society due to rotavirus disease that occurs
hen outpatient and hospitalization rates do not account for bar-
iers in access to appropriate levels of healthcare. Furthermore,
he increased access to ambulatory care might, by early diagnosis
nd treatment, prevent progression of disease to more severe pre-
entation and thus contribute to lower estimates of mortality and
ospitalization. Fourth, this analysis assumes that vaccine efﬁcacy
pproximates effectiveness. Rotavirus disease burden is greatest in
he ﬁrst two years of life and timely immunization is necessary to
chieve the anticipated effectiveness. Finally, the economic evalu-
tion presented here is a comparison of direct costs while a full cost
ffectiveness analysis would inform policy more comprehensively.
In summary, rotavirus diarrhea continues to be the most impor-
ant cause of diarrheal deaths, hospitalizations, and outpatient
isits annually for children <5 years of age in India, and is a major
conomic burden. Despite the inherent challenges in developing
ational estimates of disease and economic burden for a large and
iverse country like India, given the relative paucity of robust repre-
entative data, our estimates from these community-based cohorts
rovide the morbidity burden and the relative beneﬁt of a rotavirus
accine on both morbidity and mortality, which are not available
rom surveys or studies that have not assessed etiology. In addition
o these estimates, further research into the cost effectiveness of the
accine and the potential indirect effects of the vaccine would assist
olicy makers to decide on vaccine introduction in the national
mmunization program.
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